Director at Adaptive Biotechnologies (NASDAQ: ADPT) gets 15,625-share grant

Rhea-AI Filing Summary

Adaptive Biotechnologies Corp director Peter M. Neupert reported an acquisition of common stock through a grant or award. On March 4, 2026, he received 15,625 shares at a stated price of $0.0000 per share, bringing his directly owned holdings to 240,315 shares of common stock.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider NEUPERT PETER M

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	15,625	$0.00	--

Holdings After Transaction: Common Stock — 240,315 shares (Direct)

Footnotes (1)

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

NEUPERT PETER M

(Last) (First) (Middle)

C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION

1165 EASTLAKE AVE E

(Street)

SEATTLE WA 98109

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Adaptive Biotechnologies Corp [ ADPT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
03/04/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/04/2026		A		15,625	A	$0	240,315	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Peter M Neupert by Kyle Piskel, Attorney-in-Fact	03/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Adaptive Biotechnologies (ADPT) director Peter Neupert report?

Director Peter M. Neupert reported receiving a grant or award of 15,625 shares of Adaptive Biotechnologies common stock. The Form 4 classifies this as an acquisition transaction, increasing his directly owned holdings to 240,315 shares following the award.

How many Adaptive Biotechnologies (ADPT) shares did Peter Neupert hold after the reported Form 4 transaction?

After the reported Form 4 transaction, Peter M. Neupert directly owned 240,315 shares of Adaptive Biotechnologies common stock. This total reflects his holdings following the grant or award of 15,625 additional shares disclosed in the filing.

Was Peter Neupert’s Adaptive Biotechnologies (ADPT) transaction a market purchase or a grant?

The transaction was reported as a grant, award, or other acquisition, not a market purchase. Form 4 uses transaction code “A” and describes it as a grant or award acquisition of 15,625 common shares at a stated price of $0.0000 per share.

What type of security did Peter Neupert acquire in the Adaptive Biotechnologies (ADPT) Form 4?

Peter M. Neupert acquired shares of Adaptive Biotechnologies common stock. The Form 4 lists one non-derivative transaction involving 15,625 shares of common stock received as a grant or award, resulting in 240,315 common shares held directly after the transaction.

How is Peter Neupert’s ownership in Adaptive Biotechnologies (ADPT) classified after the Form 4 transaction?

Peter M. Neupert’s ownership is classified as direct following the transaction. The Form 4 marks the holding type as “D” for direct ownership, with 240,315 shares of Adaptive Biotechnologies common stock reported as directly owned after the grant or award.